Abstract • Of 55 aftercare patients receiving long-term treatment with antipsychotic and antiparkinson (AP) drugs, 37 were switched to being given placebo, and 18 remained on a regimen of procyclidine hydrochloride. The dose of antipsychotic was kept constant. After three weeks extrapyramidal side effects (EPS) developed in 54% of those patients receiving placebo and in none of those receiving procyclidine (P <.002): Twenty-seven percent of the placebo group had EPS without akinesia, and in the same percentage akinesia developed (P =.003). We believe the risk-benefit ratio favors the routine use of AP drugs for prophylaxis and maintenance so as to avoid misdiagnosing as psychopathology, unspontaneity due to akinesia, and to reduce unreliable pill-taking due to EPS. References 1. Cohan RB, Parrish DD: Reversibility of drug induced parkinsonism . Am J Psychiatry 116:1022-1023, 1960. 2. LaPolla A, Nash LR: Treatment of phenothiazine-induced parkinsonism with Biperiden . Curr Ther Res 7:536-541, 1961. 3. Mandel W, Oliver WA: Withdrawal of maintenance antiparkinson drug in the phenothiazine-induced extrapyramidal reaction . Am J Psychiatry 118:350-351, 1961. 4. Stratas NE, Phillips RD, Walker PA, et al: A study of drug induced parkinsonism . Dis Nerv Sys 24:180-184, 1963. 5. Hanlon TF, Schoenrich C, Freinek W, et al: Perphenozine-benztropine mesylate treatment of newly admitted psychiatric patients . Psychopharmacologia 9:328-339, 1966.Crossref 6. St Jean A, Donald MW, Ban TA: Uses and abuses of antiparkinson medication . Am J Psychiatry 120:801-803, 1964. 7. St Jean A, Donald MW, Ban TA: Interchangeability of antiparkinson medication . Am J Psychiatry 120:1189-1190, 1964. 8. DiMascio A, Demirgian E: Antiparkinson drug overuse . Psychosomatics 11:596-601, 1970.Crossref 9. Mindham RHS, Gaind R, Anstee BH, et al: Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine induced parkinsonism . Psychol Med 2:406-413, 1972.Crossref 10. Klett CJ, Caffey E: Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics . Arch Gen Psychiatry 26:374-379, 1972.Crossref 11. Orlov P, Kasparian G, DiMascio A, et al: Withdrawal of antiparkinson drugs . Arch Gen Psychiatry 25:410-412, 1972.Crossref 12. Chien CP, DiMascio A, Cole JO: Antiparkinson agents and depot phenothiazines . Am J Psychiatry 131:86-90, 1974. 13. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects . Acta Psychiat Scand ( (Suppl) ) 212:11-19, 1970.Crossref 14. Struve FA, Saraf KR, Arko RS, et al: Electroencephalographic correlates of oral contraceptive use in psychiatric patients . Arch Gen Psychiatry 33:741-745, 1976.Crossref 15. Rifkin A, Quitkin F, Klein DF: Akinesia-a poorly recognized druginduced extrapyramidal behavioral disorder . Arch Gen Psychiatry 32:672-674, 1975.Crossref 16. Rifkin A, Quitkin F, Klein DF: Fluphenazine decanoate, oral fluphenazine hydrochloride and placebo in the treatment of remitted schizophrenics: I. Relapse rate . Arch Gen Psychiatry 34:43-47, 1977.Crossref 17. Ananth JV, Jain RC: Benztropine psychosis . Can Psychiatr Assoc J 18:409-414, 1973. 18. Singh MM, Smith JM: Reversal of some therapeutic effects of an antipsychotic agent by an antiparkinsonism drug . J Nerv Ment Dis 157:50-58, 1973.Crossref 19. Singh MM, Kay SR: A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia . Psychopharmacologia 43:103-113, 1975.Crossref 20. Singh MM, Kay SR: A longitudinal comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Non therapeutic interactions with trihexyphenidyl. Theoretical-implications for potency differences . Psychopharmacologia 43:115-123, 1975.Crossref 21. Singh MM, Kay SR: Therapeutic reversal with benztropine in schizophrenics . J Nerv Ment Dis 160:258-266, 1975.Crossref 22. Kane J, Rifkin A, Quitkin F, et al: Antipsychotic drug blood levels and clinical outcome , in Klein DF, Gittleman-Klein K (eds): Progress in Psychiatric Drug Treatment , vol 2. New York, Brunner Mazel, 1976. 23. Van Putten T: Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31:67-72, 1975.Crossref
Archives of General Psychiatry – American Medical Association
Published: Apr 1, 1978
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera